Open Access to Antipsychotics in State Medicaid Programs: Effect on Healthcare Resource Utilization and Costs among Patients with Serious Mental Illness
# Background The restrictive consequences of Medicaid formulary restriction policies on antipsychotic medications may lead to higher healthcare utilization and costs among beneficiaries with serious mental illness (SMI). # Objectives This study compared outcomes among patients with SMI accessing an...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Columbia Data Analytics, LLC
2025-06-01
|
| Series: | Journal of Health Economics and Outcomes Research |
| Online Access: | https://doi.org/10.36469/001c.137909 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849771824009707520 |
|---|---|
| author | Rashmi Patel Onur Baser Heidi C. Waters Daniel Huang Leigh Morrissey Katarzyna Rodchenko Gabriela Samayoa |
| author_facet | Rashmi Patel Onur Baser Heidi C. Waters Daniel Huang Leigh Morrissey Katarzyna Rodchenko Gabriela Samayoa |
| author_sort | Rashmi Patel |
| collection | DOAJ |
| description | # Background
The restrictive consequences of Medicaid formulary restriction policies on antipsychotic medications may lead to higher healthcare utilization and costs among beneficiaries with serious mental illness (SMI).
# Objectives
This study compared outcomes among patients with SMI accessing antipsychotic medications through state Medicaid programs with open access (OA) policies (Michigan) vs 5 states without Medicaid OA policies (California, Colorado, Florida, Illinois, Wisconsin).
# Methods
A retrospective analysis was conducted using Kythera Labs Medicaid data (Jan. 1, 2016–Dec. 31, 2023). Outcomes were assessed for patients with SMI (>18 years of age, ≥1 antipsychotic medication claim during the identification period (Jan. 1, 2017–Dec. 31, 2022), ≥1 SMI claim in the 12-month baseline). Continuous medical and pharmacy benefits were required for 12 months pre- and post-index date. Outcomes included SMI-related hospital admissions, length of hospital stay, emergency department and outpatient visits, and associated costs.
# Results
A greater proportion of beneficiaries with SMI resided in Michigan than in the other states. After matching, significantly more antipsychotics users experienced SMI-related hospitalizations in California (18.25% vs 9.47%, P < .0001), Colorado (11.41% vs 7.33%, P =.0004), Florida (19.70% vs 10.17%, P < .0001), Illinois (23.57% vs 8.79%, P < .0001), and Wisconsin (15.21% vs 10.02%, P = .0046) than in Michigan. Length of stay was lower in Michigan than in California, Colorado, and Illinois. Inpatient costs related to SMI were significantly lower in Michigan, yet pharmacy costs were higher. Total SMI-related costs were higher in all non-OA states than in Michigan, except Colorado.
# Discussion
State Medicaid programs without OA to antipsychotics were associated with higher rates of SMI-related resource utilization and costs vs Michigan.
# Conclusions
Policy makers should consider the potential downstream cost implications of restrictive access policies and evaluate whether OA could result in improved health outcomes for patients and savings for Medicaid programs. |
| format | Article |
| id | doaj-art-90027ca05c52427ab91933a2a25a7d8a |
| institution | DOAJ |
| issn | 2327-2236 |
| language | English |
| publishDate | 2025-06-01 |
| publisher | Columbia Data Analytics, LLC |
| record_format | Article |
| series | Journal of Health Economics and Outcomes Research |
| spelling | doaj-art-90027ca05c52427ab91933a2a25a7d8a2025-08-20T03:02:29ZengColumbia Data Analytics, LLCJournal of Health Economics and Outcomes Research2327-22362025-06-0112110.36469/001c.137909Open Access to Antipsychotics in State Medicaid Programs: Effect on Healthcare Resource Utilization and Costs among Patients with Serious Mental IllnessRashmi PatelOnur BaserHeidi C. WatersDaniel HuangLeigh MorrisseyKatarzyna RodchenkoGabriela Samayoa# Background The restrictive consequences of Medicaid formulary restriction policies on antipsychotic medications may lead to higher healthcare utilization and costs among beneficiaries with serious mental illness (SMI). # Objectives This study compared outcomes among patients with SMI accessing antipsychotic medications through state Medicaid programs with open access (OA) policies (Michigan) vs 5 states without Medicaid OA policies (California, Colorado, Florida, Illinois, Wisconsin). # Methods A retrospective analysis was conducted using Kythera Labs Medicaid data (Jan. 1, 2016–Dec. 31, 2023). Outcomes were assessed for patients with SMI (>18 years of age, ≥1 antipsychotic medication claim during the identification period (Jan. 1, 2017–Dec. 31, 2022), ≥1 SMI claim in the 12-month baseline). Continuous medical and pharmacy benefits were required for 12 months pre- and post-index date. Outcomes included SMI-related hospital admissions, length of hospital stay, emergency department and outpatient visits, and associated costs. # Results A greater proportion of beneficiaries with SMI resided in Michigan than in the other states. After matching, significantly more antipsychotics users experienced SMI-related hospitalizations in California (18.25% vs 9.47%, P < .0001), Colorado (11.41% vs 7.33%, P =.0004), Florida (19.70% vs 10.17%, P < .0001), Illinois (23.57% vs 8.79%, P < .0001), and Wisconsin (15.21% vs 10.02%, P = .0046) than in Michigan. Length of stay was lower in Michigan than in California, Colorado, and Illinois. Inpatient costs related to SMI were significantly lower in Michigan, yet pharmacy costs were higher. Total SMI-related costs were higher in all non-OA states than in Michigan, except Colorado. # Discussion State Medicaid programs without OA to antipsychotics were associated with higher rates of SMI-related resource utilization and costs vs Michigan. # Conclusions Policy makers should consider the potential downstream cost implications of restrictive access policies and evaluate whether OA could result in improved health outcomes for patients and savings for Medicaid programs.https://doi.org/10.36469/001c.137909 |
| spellingShingle | Rashmi Patel Onur Baser Heidi C. Waters Daniel Huang Leigh Morrissey Katarzyna Rodchenko Gabriela Samayoa Open Access to Antipsychotics in State Medicaid Programs: Effect on Healthcare Resource Utilization and Costs among Patients with Serious Mental Illness Journal of Health Economics and Outcomes Research |
| title | Open Access to Antipsychotics in State Medicaid Programs: Effect on Healthcare Resource Utilization and Costs among Patients with Serious Mental Illness |
| title_full | Open Access to Antipsychotics in State Medicaid Programs: Effect on Healthcare Resource Utilization and Costs among Patients with Serious Mental Illness |
| title_fullStr | Open Access to Antipsychotics in State Medicaid Programs: Effect on Healthcare Resource Utilization and Costs among Patients with Serious Mental Illness |
| title_full_unstemmed | Open Access to Antipsychotics in State Medicaid Programs: Effect on Healthcare Resource Utilization and Costs among Patients with Serious Mental Illness |
| title_short | Open Access to Antipsychotics in State Medicaid Programs: Effect on Healthcare Resource Utilization and Costs among Patients with Serious Mental Illness |
| title_sort | open access to antipsychotics in state medicaid programs effect on healthcare resource utilization and costs among patients with serious mental illness |
| url | https://doi.org/10.36469/001c.137909 |
| work_keys_str_mv | AT rashmipatel openaccesstoantipsychoticsinstatemedicaidprogramseffectonhealthcareresourceutilizationandcostsamongpatientswithseriousmentalillness AT onurbaser openaccesstoantipsychoticsinstatemedicaidprogramseffectonhealthcareresourceutilizationandcostsamongpatientswithseriousmentalillness AT heidicwaters openaccesstoantipsychoticsinstatemedicaidprogramseffectonhealthcareresourceutilizationandcostsamongpatientswithseriousmentalillness AT danielhuang openaccesstoantipsychoticsinstatemedicaidprogramseffectonhealthcareresourceutilizationandcostsamongpatientswithseriousmentalillness AT leighmorrissey openaccesstoantipsychoticsinstatemedicaidprogramseffectonhealthcareresourceutilizationandcostsamongpatientswithseriousmentalillness AT katarzynarodchenko openaccesstoantipsychoticsinstatemedicaidprogramseffectonhealthcareresourceutilizationandcostsamongpatientswithseriousmentalillness AT gabrielasamayoa openaccesstoantipsychoticsinstatemedicaidprogramseffectonhealthcareresourceutilizationandcostsamongpatientswithseriousmentalillness |